Study of Ultrasound Contrast-Enhanced Imaging for Accurate Preoperative Staging of Bladder Cancer

What this Trial Is About

Researchers are investigating the use of ultrasound contrast enhancement, alone or combined with magnetic resonance imaging MRI, to improve the accuracy of preoperative staging in bladder cancer. Accurate staging is crucial for guiding treatment decisions, but current methods are not precise enough. This observational study builds on preliminary findings showing high diagnostic accuracy of contrast-enhanced ultrasound CEUS and aims to develop a precise diagnostic system by expanding the sample size and integrating multimodal imaging data. The study involves the use of contrast-enhanced ultrasonography, where ultrasound contrast agents like SonoVue or Lumason are injected to enhance imaging of the bladder cancer before surgery. This method will be evaluated for its ability to detect muscle invasion within the bladder, which is an important factor in staging. The research focuses on patients with confirmed primary bladder cancer who have not yet received any treatment such as surgery, chemotherapy, or immunotherapy. Participants will undergo CEUS imaging to assess tumor characteristics. Researchers will measure the accuracy of muscle invasion detection within three minutes as the primary outcome. The study includes adults aged 18 to 75 years and involves detailed diagnostic imaging without additional treatment. Safety monitoring will consider any intolerance or allergic reactions to the contrast agents. The study is expected to provide valuable data to support clinical decision-making for bladder cancer treatment planning.

Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer